Ccl22 antibody Monoclonal Antibodies Primary antibodies
- Known as:
- Ccl22 (anti-) Monoclonal Antibodies Primary antibodies
- Catalog number:
- orb45189
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- Ccl22 antibody Monoclonal Antibodies Primary antibodies
Related genes to: Ccl22 antibody Monoclonal Antibodies Primary antibodies
- Gene:
- CCL22 NIH gene
- Name:
- C-C motif chemokine ligand 22
- Previous symbol:
- SCYA22
- Synonyms:
- MDC, STCP-1, ABCD-1, DC/B-CK, A-152E5.1, MGC34554
- Chromosome:
- 16q21
- Locus Type:
- gene with protein product
- Date approved:
- 1997-08-22
- Date modifiied:
- 2016-10-05
Related products to: Ccl22 antibody Monoclonal Antibodies Primary antibodies
Related articles to: Ccl22 antibody Monoclonal Antibodies Primary antibodies
- CSF inflammatory biomarkers in Huntington disease (HD), a neurodegenerative CAG-triplet expansion disorder, usually increase with disease progression. CSF leukocytes as an inflammatory marker have not been explored in HD. We explored high-precision CSF-leukocyte counts across different HD stages in the multicenter prospective biosample HD study HDClarity and their association with CSF neurofilament light chain (NFL) and cytokine and chemokine patterns. - Source: PubMed
Publication date: 2026/08/17
Gao YuÁsbjörnsdóttir BirnaVinther-Jensen TuaVon Essen Marina RodeHellem Marie Nathalie NickelsenHjermind Lena EEjlerskov PatrickLandwehrmeyer G BernhardSellebjerg FinnNielsen Joergen ErikLewerenz Jan - Plant-derived compounds can be transformed by the human gut microbiota into postbiotic metabolites with distinct structures and biological activities, providing insight into the mechanisms underlying the pharmacological effects of medicinal plants. Among them, 5-(3',4'-dihydroxyphenyl)-γ-valerolactone (DHPV), a microbial metabolite of procyanidins, has emerged as a promising bioactive molecule with therapeutic potential. This study evaluated the potential application of synthetically produced DHPV in inflammatory conditions, focusing on its effects on inflammatory responses and wound-healing processes in skin and mucosal cell models, including keratinocytes, dermal fibroblasts, and vaginal epithelial cells. Cell viability after DHPV treatment was assessed using the MTT assay. Anti-inflammatory activity was examined in TNF-α/IFN-γ-stimulated HaCaT keratinocytes, LTA-stimulated NHDF fibroblasts, and TNF-α-stimulated VK2 vaginal epithelial cells. The effect on wound healing was evaluated using a keratinocyte scratch assay, while LC-MS-based metabolomic profiling was performed in TNF-α/IFN-γ-stimulated HaCaT cells. DHPV significantly reduced the release of pro-inflammatory mediators in all tested models, including IL-6, IL-8, CCL2, CCL22, and CCL5 in HaCaT keratinocytes; CCL2, IL-6, and IL-8 in NHDF fibroblasts; and IL-8 in VK2 cells. DHPV showed a favorable safety profile at the tested concentrations and markedly enhanced keratinocyte migration, indicating pro-regenerative activity. Metabolomic analysis revealed effects on tyrosine, histidine, and tryptophan metabolism, pathways related to cell proliferation, migration, and antioxidant defense. Overall, DHPV demonstrated anti-inflammatory and pro-healing properties, supporting its potential as a bioactive compound for inflammatory skin and mucosal conditions. - Source: PubMed
Publication date: 2026/08/12
Skowrońska WeronikaKiełkiewicz Rafał MKirzyc MajaJanowski MikołajKołodziejska JuliannaMichorowska SylwiaDawidowski MaciejKolmas JoannaGiebułtowicz JoannaGranica SebastianPiwowarski Jakub P - Macrophages are the primary host cells for Leishmania, and their polarization into either M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes determines the course of the infection. This study aimed to investigate the effects of Leishmania tropica, the main agent of cutaneous leishmaniasis (CL) in Türkiye, on the polarization of primary human macrophages. Primary monocytes were isolated from human peripheral blood and differentiated into macrophages using GM-CSF. The cells were infected with L. tropica promastigotes, analyzed after 48 h. Polarization was evaluated through morphological changes, flow cytometry for surface markers (CD80, CD163, CD206, CD209), and qPCR for gene expression of M1 (NOS2, IDO1, IRF4) and M2 (ARG1, CCL22, CCL1) markers. An infection rate of 56.5% was achieved, with infected macrophages shifting from a spindle-like morphology to a rounded and granular appearance. Flow cytometry revealed a significant decrease in the expression of M1 marker CD80 and M2 markers CD206 and CD209 (p < 0.01), while CD163 expression showed a non-significant increase. qPCR analyses demonstrated a significant down regulation of M1-related genes and a significant upregulation of the M2-related gene ARG1 (p < 0.05). The findings suggest that L. tropica infection induces a shift in macrophage polarization from an M1-like phenotype toward an M2-like phenotype, with partial resemblance to an M2c-like profile, though the concurrent decrease in CD206 and CD209 underscores the complexity of the phenotype and indicates that the activated state does not conform neatly to any single M2 subtype. This shift likely serves as an immune escape strategy, promoting parasite persistence and influencing the chronicity of CL. Further studies incorporating additional M2c subtype markers, multiple time points, and functional assays are needed. - Source: PubMed
Publication date: 2026/08/06
Taymaz NevinAl-Omar AhmedAlizadeh HamidAsadi MiladÖzbilgin AhmetÖzbel YusufTöz Seray - Topical postbiotic emollient (Strain CX) has shown efficacy for mild-to-moderate atopic dermatitis (AD) in a previous study; however, treatment responses according to allergic comorbidity status have not yet been explored. We conducted a analysis to evaluate the differential therapeutic effects of Strain CX in patients with AD stratified by the presence or absence of allergic comorbidities. This analysis was derived from a randomized, double-blind, vehicle-controlled trial (Clinical Research Information Service of South Korea, KCT0007876). A total of 98 patients with mild-to-moderate AD were stratified into placebo (n = 33), AD without allergic comorbidities (n = 29), and AD with allergic comorbidities (n = 36) groups. The primary outcomes were the Investigator's Global Assessment (IGA) score and the proportions of participants achieving 25% or 50% improvement in the Eczema Area and Severity Index (EASI), assessed at weeks 4 and 8. The secondary outcomes included a range of skin-related clinical and molecular measures, along with additional evaluations of serum inflammatory and allergic biomarkers as laboratory measures in the per-protocol analysis set. At week 8, 55.2% (16/29) of participants in the AD without allergic comorbidities group achieved an IGA score of 0 or 1 with ≥ 1 point reduction, compared to 30.6% (11/36) in the AD with allergic comorbidities group ( = 0.0272). Both Strain CX intervention groups showed significant improvements in skin parameters, including EASI, skin moisture, and transepidermal water loss. Notably, the AD with allergic comorbidities group solely exhibited significant reductions in systemic inflammatory markers, including sIL-2R (mean, -231.19; 95% confidence interval [CI], -378.82 to -83.57 pg/mL), CCL17 (-127.05; 95% CI, -251.80 to -2.31 pg/mL), and CCL22 (-578.40; 95% CI, -939.31 to -217.49 pg/mL). Clinical skin responses improved more in patients with AD without allergic comorbidities, while immunomodulatory benefits were observed in those with allergic comorbidities. These findings support patient stratification based on allergic comorbidity status for personalized Strain CX treatment strategies. Trial Registration: Clinical Research Information Service Identifier: KCT0007876. - Source: PubMed
Kang JiseungYim YesolLee HaeunKang So MinLee Dong-GeolHeo Young MokJo HyungwooKang SeunghyunKim Hyeon JinYon Dong KeonNehs Christa J - Cyclopropanes are prevalent motifs in pharmaceuticals and natural products; however, the construction of complex cyclopropanes remains a longstanding issue owing to low intrinsic reactivity and steric congestion. Herein, we report a visible-light-mediated cyclopropanation of unactivated alkenes with diazo compounds an energy-transfer (EnT) pathway. This protocol provides direct access to a range of cyclopropanes, including spirocyclic, fused and those bearing quaternary carbon centers. Notably, a broad spectrum of unactivated alkenes-spanning endocyclic, bridged, polysubstituted, and terminal systems, along with diverse diazo reagents-are well tolerated, underscoring the generality of the method. The practicality is demonstrated by gram-scale synthesis and late-stage modification of natural products such as valencene, β-caryophyllene and flavanone. Moreover, in a preliminary assay, the caryophyllene oxide derivative exhibits promising anti-atopic dermatitis activity, showing nearly twice as high inhibition of CCL17 and CCL22 compared to its precursor, while exhibiting no detectable cytotoxicity. Finally, mechanistic studies support the involvement of triplet carbene species. These findings highlight the potential of this photochemical strategy for the rapid construction of challenging cyclopropanes and its utility in the development of bioactive natural product analogues. - Source: PubMed
Publication date: 2026/07/21
Zhang LeZhang NaWang DinggangYuan XiaoHan XinyuZhuo MiaomiaoGuo GuangyangZhang Wei-DongZhang HaoZhang Yu